PTC Therapeutics

Press Releases

The press releases contained in this archive section are provided for historical purposes only. The information contained in each press release is accurate only as of the date each press release was originally issued. PTC Therapeutics disavows any obligation to update the information contained in such press releases after the date of their issuance.

 
Press Releases
  Date Title and Summary View
Jan 3, 2017
SOUTH PLAINFIELD, N.J., Jan. 3, 2017 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that the company will present a corporate update at the upcoming 35th Annual J.P. Morgan Healthcare Conference on Wednesday, January 11, 2017 at 7:30 am PT. The presentation will be webcast live on the Events and Presentations page und...
Dec 16, 2016
SOUTH PLAINFIELD, N.J., Dec. 16, 2016 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that on December 14, 2016 it approved non-statutory stock options to purchase an aggregate of 5,600 shares of its common stock to two new employees. The awards were made pursuant to the NASDAQ inducement grant exception as a component of our ...
Dec 8, 2016
SOUTH PLAINFIELD, N.J., Dec. 8, 2016 /PRNewswire/-- PTC Therapeutics Inc. (NASDAQ: PTCT), today announced that the company received France's 2016 Prix Galien for Translarna™ (ataluren) for the treatment of nonsense mutation Duchenne muscular dystrophy (nmDMD) in the Medicines "Rare Disease" category. The award recognizes the scientific innova...
Nov 18, 2016
SOUTH PLAINFIELD, N.J., Nov. 18, 2016 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that on November 17, 2016 it approved non-statutory stock options to purchase an aggregate of 33,600 shares of its common stock to eight new employees. The awards were made pursuant to the NASDAQ inducement grant exception as a component of o...
Nov 11, 2016
SOUTH PLAINFIELD, N.J., Nov. 11, 2016 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has recommended the renewal of the conditional marketing authorization of Translarna™ (ataluren) for the treatment of nonsense mutatio...
Nov 2, 2016
SOUTH PLAINFIELD, N.J., Nov. 2, 2016 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced a corporate update and reported financial results for the third quarter ending September 30, 2016. "For the past 18 years, we have focused significant effort towards developing Translarna for those affected by Duchenne," stated Stuart ...
Oct 20, 2016
SOUTH PLAINFIELD, N.J., Oct. 20, 2016 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that its joint development program in Spinal Muscular Atrophy (SMA) with Roche (SIX: RO, ROG; OTCQX: RHHBY) and the SMA Foundation (SMAF) initiated a Phase 2 study in pediatric and adult Type 2/3 SMA patients. The study, named SUNFISH, is a t...
Oct 19, 2016
SOUTH PLAINFIELD, N.J., Oct. 19, 2016 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that the Company will host a webcast conference call to report its third quarter financial results and provide an update on the company's business and outlook on Wednesday, November 2, 2016 at 4:45 p.m. (ET) after the closing of the market. ...
Oct 17, 2016
SOUTH PLAINFIELD, N.J., Oct. 17, 2016 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today provided a regulatory update on Translarna™ (ataluren) for the treatment of nonsense mutation Duchenne muscular dystrophy (nmDMD). U.S. regulatory update PTC Therapeutics announced today that at the end of last week, the Office of ...
Oct 6, 2016
SOUTH PLAINFIELD, N.J., Oct. 6, 2016 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced new data supporting the potential benefit of ataluren in preserving lung function in non-ambulatory nonsense mutation Duchenne muscular dystrophy patients (nmDMD). The results, which are being presented today as part of a company-sponsored sym...
Page: FirstPrevious
3
... NextLast
= add release to Briefcase
You are now leaving this website. If you would like to continue, click Continue.
CancelContinue